Cirius Therapeutics is a clinical-stage company that develops insulin sensitizer for the treatment of non-alcoholic steatohepatitis. The company developing MSDC-0602K, a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH). MSDC-0602K is currently being evaluated in a Phase 2b clinical trial. Through its novelinsulin-sensitizing mechanism of action, MSDC-0602K has the potential to resolve the underlying pathophysiology of NASH.Circius Therapeutics focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases. It was founded in 2015 and is based in Kalamazoo, Michigan, United States.

Biotechnology

Pharmaceutical

Therapeutics

Cirius Therapeutics

Bob Baltera

Angeline Shashlo

Jerry Colca

The Scientific Advisory Team at Cirius Therapeutics consists of experts who provide strategic advice on the scientific and clinical aspects of drug development. They guide the research and development of MSDC-0602K, offering insights on study design, regulatory pathways, and potential therapeutic applications to ensure the advancement of innovative therapies for liver and metabolic diseases.

Scientific Advisory Team

About

Team members

Other teams at Cirius Therapeutics

Leadership Team